|
|
Post by prcgorman2 on Nov 1, 2024 13:27:57 GMT -5
^ "revenue tied to improving manufacturing capacity" The money (from UTHR to MNKD) to pay for more and improved manufacturing equipment goes into deferred revenue. Deferred revenue is then "recognized" (added to C&S) over a long period of time. This category will not cause large short term variations in C&S. But manufacturing cost-per-unit can decrease as efficiencies result from improving the manufacturing process. So, with increasing units being sold yet at lower cost, the "cost of manufacture" component of C&S can go flat. But that is a separate category within C&S. UTHR reported an increase in the charged price of Tyvasso DPI on their earnings report. Could you tell if that was a price hike in the product, or more product shipped? I'm hoping the latter. |
|
|
|
Post by peppy on Nov 1, 2024 13:37:36 GMT -5
"Total Tyvaso revenues grew by 33 percent to $433.8 million in the third quarter of 2024, compared to $325.8 million in the third quarter of 2023. This growth was primarily due to an increase in quantities sold, driven by the commercial launch of Tyvaso DPI in June 2022 and continued growth in commercial utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, price increases.
The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase. The increase in Tyvaso DPI quantities sold was due to continued growth in the number of patients following the product’s launch and, to a lesser extent, increased commercial utilization following the implementation of the Part D redesign under the Inflation Reduction Act (IRA)." ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2024/2024-10-30-uthr-3q24-earnings-release.pdf |
|
|
|
Post by mpg54 on Nov 7, 2024 0:52:46 GMT -5
Hope tomorrow is not a sell-the-news day, good or bad. We've had such a nice run, would be nice if it at least holds the 7's, and even better if we continue up...
|
|
|
|
Post by sla55 on Nov 7, 2024 16:10:39 GMT -5
|
|
|
|
Post by mpg54 on Nov 7, 2024 16:20:47 GMT -5
Seems Colab Services came in short, but this was somewhat expected. The drop in Afrezza sales was not. I am misssing something?
|
|
|
|
Post by castlerockchris on Nov 7, 2024 16:28:58 GMT -5
Seems Colab Services came in short, but this was somewhat expected. The drop in Afrezza sales was not. I am misssing something? Are you suggesting there was a drop in Afrezza sales compared to year earlier? $15 mm compared to 13.5mm for the Q3 2023. Am I the one missing something? |
|
|
|
Post by mpg54 on Nov 7, 2024 16:35:48 GMT -5
Seems Colab Services came in short, but this was somewhat expected. The drop in Afrezza sales was not. I am misssing something? Are you suggesting there was a drop in Afrezza sales compared to year earlier? $15 mm compared to 13.5mm for the Q3 2023. Am I the one missing something? I was comparing to last QTR, hoping to see steady rise in Rev... 16,289 |
|
|
|
Post by tarheelblue004 on Nov 7, 2024 17:36:11 GMT -5
I am really liking the earnings growth! YTD $20M GAAP Net Income and $45M Non-GAAP Net Income is great. The business is starting to really flourish, and the growth ahead looks so nice - even more so as %s...
GAAP Non-GAAP
Q2, 2023 1.7 7.6
Q3, 2023 5 4.2
Q4, 2023 7.8 7.9
Q1, 2024 10.6 15.5
Q2, 2024 -2 14.3
Q3, 2024 11.5 15.3
|
|
|
|
Post by parrerob on Nov 8, 2024 9:00:13 GMT -5
I think it was a good quarter and I absolutely agree with the importance of profits rather than total revenues. As someone had imagined, the part of revenue relating to collaborations has started to decline but without affecting the EPS part which is instead always on a positive trend.
Two points disappointed me from the results of this call....
The main point is to realize the fact that the presentation of the study at the ADA event and all the publicity following that event did not influence Afrezza's prescriptions in the slightest in the following 3.5 months, in fact they even contracted slightly.
The other point is related to India and its non-mention during the call.... although it still appears in the pipeline.
|
|
|
|
Post by prcgorman2 on Nov 8, 2024 9:19:09 GMT -5
I think it was a good quarter and I absolutely agree with the importance of profits rather than total revenues. As someone had imagined, the part of revenue relating to collaborations has started to decline but without affecting the EPS part which is instead always on a positive trend. Two points disappointed me from the results of this call.... The main point is to realize the fact that the presentation of the study at the ADA event and all the publicity following that event did not influence Afrezza's prescriptions in the slightest in the following 3.5 months, in fact they even contracted slightly. The other point is related to India and its non-mention during the call.... although it still appears in the pipeline. Mike mentioned an 8% improvement in Afrezza scripts but I didn’t re-listen to that section to hear what he was talking about. Mike didn’t specifically mention Cipla by name, but there was mention of international sales of Afrezza which I have to believe is India. |
|
|
|
Post by dh4mizzou on Nov 8, 2024 9:25:24 GMT -5
So what is happening with Brazil?
|
|
|
|
Post by parrerob on Nov 8, 2024 10:01:52 GMT -5
I think it was a good quarter and I absolutely agree with the importance of profits rather than total revenues. As someone had imagined, the part of revenue relating to collaborations has started to decline but without affecting the EPS part which is instead always on a positive trend. Two points disappointed me from the results of this call.... The main point is to realize the fact that the presentation of the study at the ADA event and all the publicity following that event did not influence Afrezza's prescriptions in the slightest in the following 3.5 months, in fact they even contracted slightly. The other point is related to India and its non-mention during the call.... although it still appears in the pipeline. Mike mentioned an 8% improvement in Afrezza scripts but I didn’t re-listen to that section to hear what he was talking about. Mike didn’t specifically mention Cipla by name, but there was mention of international sales of Afrezza which I have to believe is India. Hey Prcgorman I believe Mike was comparing Afrezza Sales vs Q3 2023...... What is disappointing is comparison with Q2 2024...... Mike did not mentioned |
|
|
|
Post by parrerob on Nov 8, 2024 10:50:50 GMT -5
|
|
|
|
Post by agedhippie on Nov 8, 2024 15:48:54 GMT -5
Looking at the call I don't understand this line as I think it would be a good thing, not bad. Was this really what Mike said?
Unfortunately, as we look out in the space, MannKind is one of the last remaining companies outside of Insmed investing in NTM at this point due to the failures of several competitors this past year.
As a general point, and not just because of Afrezza, this line was interesting:
and one of our specialty pharmacies was told to shift patients back out to retail by Optum for all of their patients, not just Afrezza.
The PBMs don't control the pricing in specialty pharmacies and they want to get that under control before their customers start asking why a drug is cheaper from a specialty pharmacy and want that price established as the list price. That would cut into PBMs profits since their commission is based on the difference between list and paid price.
This will be really interesting re: INHALE-3 data
-- the 30-week data just came out a few weeks ago here. And that data will be published in a reputable journal probably in the next four to eight weeks.
|
|
|
|
Post by Clement on Nov 8, 2024 16:15:28 GMT -5
^ I took that "unfortunately" to mean something like the following: It is unfortunate for the patient to have fewer treatment options after the failures of several competitors last year.
|
|
